Menu
BOSTON and LAUSANNE, Switzerland, Aug. 30, 2021 -- SOPHiA GENETICS SA (Nasdaq: SOPH), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.
SOPHiA GENETICS’ management is scheduled to present on Friday, September 10th at 9:30 a.m. Eastern Time/3:30 p.m. Central European Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: ir.sophiagenetics.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.
Availability of Other Information About SOPHiA GENETICS:
Investors and others should note that SOPHiA GENETICS communicates with its investors and the public using its company website (SOPHiAGENETICS.COM) as well as other channels, including but not limited to U.S. Securities and Exchange Commission filings, press releases, presentations, public conference calls and webcasts. The information SOPHiA GENETICS communicates through these channels could be deemed to be material information. As a result, SOPHiA GENETICS encourages investors and others interested in SOPHiA GENETICS to review the information it disseminates through these channels on a regular basis.
Investor Contact:
Carrie Mendivil
[email protected]
Media Contact:
[email protected]
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
